Carbenoxolone sodium for gastric ulcer.
D001581:Benzothiadiazines; D001835:Body Weight / Q000187:drug effects; D002229:Carbenoxolone / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004232:Diuretics; D004381:Duodenal Ulcer / Q000188:drug therapy; D006333:Heart Failure / Q000139:chemically induced; D006801:Humans; D006929:Hyperaldosteronism / Q000139:chemically induced; D006973:Hypertension / Q000139:chemically induced; D007008:Hypokalemia / Q000139:chemically induced; D049993:Sodium Chloride Symporter Inhibitors / Q000627:therapeutic use; D013148:Spironolactone / Q000627:therapeutic use; D013276:Stomach Ulcer / Q000188:drug therapy*; D014315:Triterpenes / Q000627:therapeutic use*
D001581:Benzothiadiazines; D004232:Diuretics; D049993:Sodium Chloride Symporter Inhibitors; D014315:Triterpenes; D013148:Spironolactone; D002229:Carbenoxolone